Results 11 to 20 of about 14,826 (163)

Effect of Combination Therapy with Ezetimibe and Statins versus Statin Monotherapy on Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Medicina, 2023
Background and Objectives: Lipid-lowering agents such as ezetimibe are recommended in uncontrolled hyperlipidemia for primary and secondary prevention of cardiovascular disease.
Ryuk Jun Kwon, Young Hye Cho, Eun Ju Park, Youngin Lee, Sae Rom Lee, Jung In Choi, Sang Yeoup Lee, Soo Min Son   +7 more
doaj   +1 more source

Ezetimibe inhibits triple-negative breast cancer proliferation and promotes cell cycle arrest by targeting the PDGFR/AKT pathway

Heliyon, 2023
Cholesterol levels were strongly associated with tumor progression and metastasis. Targeted cholesterol metabolism has broad prospects in tumor treatment.
Qinyu He, Lingkai Kong, Weiwei Shi, Ding Ma, Kua Liu, Shuwei Yang, Qilei Xin, Chunping Jiang, Junhua Wu   +8 more
doaj   +1 more source

Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia [PDF]

The Korean Journal of Internal Medicine, 2023
Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels.
Jeongmin Lee, Seung-Hwan Lee
doaj   +1 more source

Ezetimibe [PDF]

Circulation, 2018
Article, see p 1571 IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), conducted in 18 144 participants who had recently experienced an acute coronary syndrome, demonstrated that the addition of ezetimibe 10 mg to simvastatin 40 mg, both taken daily, reduced low-density lipoprotein (LDL) cholesterol by an additional 16
William G, Herrington, David, Preiss, Jane, Armitage   +2 more
openaire   +3 more sources

Ezetimibe ameliorates clinical symptoms in a mouse model of ankylosing spondylitis associated with suppression of Th17 differentiation

Frontiers in Immunology, 2022
Ankylosing spondylitis (AS) is a chronic inflammatory disease that causes spinal inflammation and fusion. Although the cause of AS is unknown, genetic factors (e.g., HLA-B27) and environmental factors (e.g., sex, age, and infection) increase the risk of ...
Jeonghyeon Moon, Seon-Yeong Lee, Seon-Yeong Lee, Hyun Sik Na, Hyun Sik Na, Hyun Sik Na, A Ram Lee, A Ram Lee, A Ram Lee, Keun-Hyung Cho, Keun-Hyung Cho, Keun-Hyung Cho, Jeong Won Choi, Jeong Won Choi, Sung-Hwan Park, Mi-La Cho, Mi-La Cho, Mi-La Cho, Mi-La Cho   +18 more
doaj   +1 more source

Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance

Frontiers in Cardiovascular Medicine, 2022
BackgroundStatins are the most widely prescribed medication to lower low-density lipoprotein cholesterol (LDL-c). However, a significant portion of patients are unable to tolerate them due to side effects, most commonly muscle related.
Natalie C. Ward, Christopher M. Reid, Gerald F. Watts, Gerald F. Watts   +3 more
doaj   +1 more source

Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects

BMC Pharmacology and Toxicology, 2023
Background Ezetimibe is a new class of antihyperlipidemic agent indicated for the prevention of atherosclerosis disease and for the treatment of hypercholesterolemia.
Feifei Sun, Yanping Liu, Ting Li, Pingping Lin, Xin Jiang, Xin Li, Chenjing Wang, Xiaomeng Gao, Yaping Ma, Yao Fu, Yu Cao   +10 more
doaj   +1 more source

Impact of combination therapy with statin and ezetimibe on secondary prevention for post-acute myocardial infarction patients in the statin era

International Journal of Cardiology: Heart & Vasculature, 2015
Background: Little is known concerning the effect of ezetimibe for secondary prevention in post-myocardial infarction (MI) patients. In this study, we investigated the secondary prevention effect of ezetimibe for post-MI patients.
Soichiro Ebisawa, Atsushi Izawa, Yasushi Ueki, Hirofumi Hioki, Masatoshi Minamisawa, Naoto Hashizume, Naoyuki Abe, Yuichiro Kashima, Takashi Miura, Takahiro Takeuchi, Hirohiko Motoki, Ayako Okada, Yusuke Miyashita, Jun Koyama, Uichi Ikeda   +14 more
doaj   +1 more source

Densitometric Determination of Ezetimibe in the Presence of its Alkaline Degradation Product [PDF]

Journal of Advanced Pharmacy Research, 2018
Objectives: A simple, accurate, selective and sensitive densitometric method was developed for the determination of ezetimibe in the presence of its alkaline degradation product.
khalid Attia, Ashraf Abdelfattah, Nasr Elabasawi, Ahmad Abo-serie, Samir Morshedy   +4 more
doaj   +1 more source

Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021

Frontiers in Cardiovascular Medicine, 2022
AimsAddition of ezetimibe to statin therapy is recommended by current guidelines when low-density lipoprotein cholesterol (LDL-C) targets are not achieved with statin monotherapy.
Julius L. Katzmann, Marita Kieble, Salka Enners, Michael Böhm, Felix Mahfoud, Ulrich Laufs, Martin Schulz, Martin Schulz   +7 more
doaj   +1 more source